SecBot SecBot
6-K ·Filed Sep 14, 2026

TLX

Telix Pharmaceuticals Ltd
BULLISH
Impact 8/10
Horizonweeks Processed2mo ago SEC0001628280-26-061892
Notable filing: 6-K
Actionable Insight ▲ Bullish

The FDA approval of Pixclara is a major commercial catalyst that should drive near-term revenue growth and de-risk the stock. Traders should watch for initial U.S. sales data, reimbursement decisions, and updates on the Phase 3 brain metastases expansion study.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$12.83
T+0 close · Sep 14, 2026 · via day close
Latest settled
−14.89%
T+20 · $10.92 · next T+60 in 22d
Vs SPY
−17.61%
α at T+20
Latest observation
−24.45%
T+42 · FF3 residual α
  1. T+0 · Sep 15 $12.83entry
  2. T+1 · 2mo ago −7.79%α −7.35% · $11.83
  3. T+5 · 8w ago −6.86%α −8.99% · $11.95
  4. T+20 · 5w ago −14.89%α −17.61% · $10.92
  5. T+44 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer). This is a transformative regulatory milestone that opens a new commercial product line in a large, underserved U.S. market (~24,000 new glioma cases/year) and reinforces Telix's leadership in theranostics. The approval is a clear, material positive catalyst for the stock.

Key Facts

  • FDA approved Pixclara (floretyrosine F 18) for PET imaging to differentiate recurrent/progressive glioma from treatment-related change in adults and pediatric patients 1 month+
  • Pixclara is the first and only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer)
  • Approximately 24,000 new glioma cases are diagnosed annually in the U.S., representing a significant addressable market
  • FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines
  • Pixclara expands Telix's commercial precision diagnostics portfolio alongside Illuccix and Gozellix
  • Pixclara (TLX101-Px) is also in a Phase 3 registrational study for potential indication expansion in brain metastases

Financial Impact

Opens a new commercial revenue stream in a ~24,000-patient/year U.S. market for the first FDA-approved glioma PET imaging agent; no specific revenue guidance or pricing provided in the filing

revenueproduct portfolio

Risk Factors

  • Commercial adoption and reimbursement may be slower than expected
  • Competition from other imaging modalities or future FDA-approved products
  • Pixclara is a diagnostic agent; revenue contribution may be modest relative to therapeutic pipeline
  • Phase 3 brain metastases study may not succeed

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-061892
Document: pixclaraapprovalvfinal.htm0001628280-26-061892
Document: 0001628280-26-061892-index-headers.html0001628280-26-061892
Document: 0001628280-26-061892-index.html0001628280-26-061892
Document: 0001628280-26-061892.txt0001628280-26-061892

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 19 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Viewing Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026